The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple sclerosis.

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate privosegtor (formerly known as OCS-05) for the treatment of optic neuritis (ON). 1 ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

The study looked at the potential benefits of cataract surgery in patients with a prior diagnosis of optic neuropathy. Patients with and without optic neuropathies showed significant improvement in ...

Please provide your email address to receive an email when new articles are posted on . One physician said intravenous corticosteroids are useful for treating optic neuritis. Another argued ...

DUBLIN--(BUSINESS WIRE)--The "Optic Neuritis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive information on the ...

A 71-year-old man was referred by his usual ophthalmologist to the neuro-ophthalmology clinic at Tufts Medical Center for bilateral decreased vision associated with bilateral optic disc edema. His ...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

—A large data analysis found a significantly heightened relative risk of optic neuritis in NMOSD, MOGAD, and other inflammatory diseases, supporting prompt evaluation of visual complaints in these ...

ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant ...